Benzodiazepine and Z-Drug Safety Guideline

Major Changes January 2022 .............................................................................................................................................. 2
Expectations for KFHPWA Providers .................................................................................................................................. 2
Background ........................................................................................................................................................................ 2
Prescribing ........................................................................................................................................................................ 4
Management of Patients on Chronic Benzodiazepines or Z-Drugs .................................................................................. 7
Tapering and Discontinuation ................................................................................................................................................. 10
Treatment of Withdrawal Symptoms .................................................................................................................................. 13
Referral Criteria ..................................................................................................................................................................... 14
Evidence Summary .................................................................................................................................................................. 15
References ............................................................................................................................................................................... 22
Guideline Development Process and Team .......................................................................................................................... 26

Appendix 1
  Table A. Long-acting benzodiazepine comparison ........................................................................................................ 27
  Table B. Intermediate-acting benzodiazepine comparison ................................................................................................. 28
  Table C. Short-acting benzodiazepine comparison ............................................................................................................. 29

Last guideline approval: January 2022

Guidelines are systematically developed statements to assist patients and providers in choosing appropriate health care for specific clinical conditions. While guidelines are useful aids to assist providers in determining appropriate practices for many patients with specific clinical problems or prevention issues, guidelines are not meant to replace the clinical judgment of the individual provider or establish a standard of care. The recommendations contained in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient.
Major Changes as of January 2022

- Tapering recommendations for benzodiazepine and Z-drug tapering have been updated.
- Benzodiazepine dose equivalencies to diazepam have been updated.
- New prescribing quantity limits for benzodiazepines and Z-drugs have been added.
- This FDA boxed warning about benzodiazepines has been added: “As of September 2020, the FDA requires that all benzodiazepine prescriptions include a boxed warning that addresses the serious risks of abuse, addiction, physical dependence, and withdrawal reactions of benzodiazepine medicines.”

Expectations for Kaiser Foundation Health Plan of Washington Providers

Using protocols and standard documentation, Kaiser Foundation Health Plan of Washington aims to minimize practice variation in the management of patients on chronic benzodiazepine therapy to improve patient safety and increase both patient and provider satisfaction.

✔️ **Patients should not be prescribed benzodiazepines if currently taking any opioid.**
  See “Tapering and Discontinuation,” p. 10.

✔️ **Benzodiazepines should not be combined** with another benzodiazepine, Z-drug, or muscle relaxant.

✔️ Patients treated with chronic benzodiazepines are risk-stratified to the highest appropriate category by the prescribing clinician and the risk level is documented on the Epic dashboard.

✔️ Patients prescribed chronic benzodiazepines shall have regular monitoring visits that:
  - Occur at a frequency based on the patient’s risk stratification, and

✔️ Patients on chronic benzodiazepines shall receive all benzodiazepine prescriptions from one physician and one pharmacy whenever possible. Clinicians treating a patient on chronic benzodiazepines are expected to clarify and document—both among themselves and with the patient—which clinician holds primary prescribing responsibility.

Background

Benzodiazepines and Z-drugs (i.e., newer GABA receptor agonists, like zolpidem [Ambien]) are overprescribed, and many prescription treatment plans are not supported by scientific evidence or published guidelines. Despite warnings about the risks of long-term use of benzodiazepines, millions of prescriptions are still issued for benzodiazepines and Z-drugs each year. As a result, clinicians may encounter patients who have been prescribed benzodiazepines or Z-drugs on a long-term basis and are averse to discontinuing these treatments.

The purpose of this guideline is fivefold:

- To reduce inappropriate prescribing of benzodiazepines and Z-drugs,
- To clarify when short-term prescribing of benzodiazepines and Z-drugs may be indicated,
- To confirm that long-term use of benzodiazepines and Z-drugs is rarely, if ever, indicated,
- To aid primary care and mental health providers in identifying and managing patients on long-term benzodiazepines and Z-drugs, and
- To provide appropriate advice to providers for discontinuing benzodiazepine and Z-drug use.

This guideline is in alignment with the National Permanente Medical Group 2021 Practice Recommendations for Benzodiazepines & Non-Benzodiazepine Sedative-Hypnotics/Z drugs.
Target population
The recommendations in this guideline apply to patients who are:
- Already on prescribed long-term benzodiazepine or Z-drug therapy, or
- Being considered for initiation of short-term therapy with either drug class.

Exclusions
This guideline does not apply to:
- Patients who are using benzodiazepines illicitly. These patients may require treatment by an addiction specialist or chemical dependency treatment provider and should be referred to Mental Health and Wellness.
- Patients who are using benzodiazepines for treatment of alcohol withdrawal. See the KPWA Unhealthy Drinking in Adults Guideline.
- Patients who are using benzodiazepines for treatment of seizure disorder.
- Patients receiving palliative, hospice, or other end-of-life care.
- Other situations for which benzodiazepines may be appropriate:
  - Urgent treatment of acute psychosis with agitation or acute mania
  - Single-dose treatment of phobias, such as flying phobia
  - Sedation for procedures
  - Spasticity treatment

About benzodiazepines and Z-drugs
Benzodiazepines are gamma-aminobutyric acid (GABA) receptor agonists that have hypnotic, anxiolytic, muscle relaxant, and anticonvulsant properties. Benzodiazepines are commonly divided into three groups according to how quickly they are eliminated from the body:
- Short-acting (half-life less than 12 hours), such as midazolam and triazolam.
- Intermediate-acting (half-life between 12 and 24 hours), such as alprazolam, lorazepam, and temazepam.
- Long-acting (half-life greater than 24 hours), such as diazepam, clonazepam, clorazepate, chlordiazepoxide, and flurazepam.

Z-drugs (e.g., zaleplon, zolpidem, and eszopiclone) were developed as alternatives to benzodiazepines.
- Like benzodiazepines, they are GABA receptor agonists, but because they have a different structure they produce fewer anxiolytic and anticonvulsant effects.
- Z-drugs are not “safer” than benzodiazepines, and patients on benzodiazepines should not be switched to Z-drugs to try to improve safety. (See drug alerts on next-day sedation with zolpidem and eszopiclone.)

Both benzodiazepines and Z-drugs are considered a “high-risk medication in the elderly” and are listed on the American Geriatrics Society Beers Criteria list.

Chronic benzodiazepine use is daily or near-daily use of benzodiazepines for at least 90 days and often indefinitely, and is defined as a minimum 70-day supply of benzodiazepines dispensed in the previous 3 calendar months.

Chronic Z-drug use is daily or near-daily use of Z-drugs for at least 90 days and often indefinitely, and is defined as a minimum 70-day supply of Z-drugs dispensed in the previous 3 calendar months.
Prescribing

Except where noted, statements about benzodiazepines in this guideline also apply to Z-drugs.

**Prescribing quantity limits** (See huddle card)

- The default in KP HealthConnect for acute benzodiazepine (or Z-drug) prescribing limit is 7 tabs/caps.
- For benzodiazepine-naïve patients (≤ 7-day supply within last 180 days), the maximum supply is 15 tabs/caps or 14-day supply (whichever is the lesser amount). There is currently no equivalent limit for Z-drugs.
- Benzodiazepine and Z-drug prescriptions are limited to a 30-day supply.

In addition to prescribing quantity limits, the following Best Practice Alerts fire in HealthConnect to alert providers when:

- A benzodiazepine (or Z-drug) is prescribed to a patient 65 years or older
- A second benzodiazepine prescription (or Z-drug) is ordered within 60 days (transition to chronic)
- A benzodiazepine (or Z-drug) is ordered when the patient is already taking an opioid
- A second benzodiazepine (or benzo + Z-drug) is ordered for a patient who is already taking a benzodiazepine

Prescribing considerations

Before initiating a course of benzodiazepine treatment, the following should be considered:

- Do not prescribe benzodiazepines to patients already taking opioids, as this is associated with increased risk of fatal overdose.
- Concurrent use of marijuana and benzodiazepines is not recommended.
- Explicitly advise the patient regarding the duration of treatment. Use of benzodiazepines beyond 2 weeks is not recommended.
- Use the lowest dose for the shortest time.
- Review with the patient the risks and side effects, including the risk of dependence. Keep in mind that some patients will have difficulty discontinuing the medication at the end of acute treatment.
- Discuss exit strategies, such as tapering and/or transition to alternative treatments.
- Discuss alternative treatments, which may include:
  - Antidepressant medications (e.g., SSRIs, SNRIs, tricyclic antidepressants)
  - Psychotherapy (e.g., cognitive behavioral therapy)
  - Serotonergic agents for anxiety (e.g., buspirone)
  - Anticonvulsant medications for restless leg syndrome (e.g., pramipexole, ropinirole, gabapentin)
- The patient and health care provider should agree on one provider to be the benzodiazepine prescriber for that patient. This designated prescriber should also be responsible for prescribing other medications with abuse potential, specifically central nervous system (CNS) stimulants and narcotics; otherwise the prescriber of benzodiazepines should closely coordinate care with those who are prescribing other controlled substance medications.
- For patients who are prescribed chronic benzodiazepines for anxiety at a dose exceeding the maximum dose listed in Appendix 1, consultation with a psychiatrist is recommended.
Note for patients aged 65 years and over

- If prescribing for patients who are frail or aged ≥ 65 years, consider initiating the medication at half the adult dose.
- Individuals aged ≥ 65 years are especially vulnerable to the adverse effects of hypnotic drugs, as metabolic capacities and rates decline with age. Patients in this age group are:
  - More susceptible to CNS depression and cognitive impairment, and may develop confusion states and ataxia, leading to falls and hip fractures.
  - At risk of drug interaction with other medications.
  - At risk of permanent cognitive impairment when using high doses of benzodiazepines (e.g., diazepam 30 mg or equivalent) on a regular basis.

Short-term use

In rare circumstances of acute, severe, and debilitating insomnia that is not responsive to behavioral treatment, a one-time supply of ≤ 15 pills zolpidem 5 mg at bedtime for a brief period while the patient’s evidence-based behavioral insomnia treatment is being adjusted, with no refills, is recommended. Ensure recommendations in the KPWA Insomnia Guideline have been followed prior to consideration of higher-risk treatments.

- Physical dependence rapidly occurs within 2 weeks of continuous daily use.
- Avoid in patients taking opioids and other sedative-hypnotics or substances with sedative effects such as alcohol, due to an increased risk of respiratory depression.
- Avoid in patients aged 65 years and over, due to increased adverse effects including fall risks and cognitive impacts.

Long-term use

Benzodiazepines and Z-drugs are not recommended for long-term use (longer than 2 weeks), except in exceptional circumstances (e.g., for terminally ill patients). There is no evidence to support the long-term use of these drugs for insomnia or any mental health indication. There are concerns regarding their safety.

- Insomnia: The treatment period should not exceed 2 weeks, as sleep studies have shown that sleep patterns return to pre-treatment levels after only a few weeks of regular use.
- Anxiety: Continuing beyond 2 weeks will result in loss of effectiveness, development of tolerance or dependence, potential for withdrawal symptoms, persistent adverse effects, and interference with the effectiveness of definitive medications and counseling.

Contraindications

- Concurrent use of another benzodiazepine, Z-drug, muscle relaxant, or opioid
- Active or history of substance use disorder
- Pregnancy or risk of pregnancy
- Treatment with opioids for chronic pain or agonist therapy for opioid use disorder
- Medical and mental health problems that may be aggravated with benzodiazepines, such as fibromyalgia, chronic fatigue syndrome, somatization disorders, depression, bipolar disorders (except for urgent sedation in acute mania), attention deficit hyperactivity disorder, kleptomania, and other impulse disorders
- Cardiopulmonary disorders such as asthma, sleep apnea, chronic obstructive pulmonary disease, and congestive heart failure, as benzodiazepines may worsen hypoxia and hypoventilation

Adverse effects of benzodiazepines

- There is an association between benzodiazepine use and dementia, increased rate of falls, and increased risk of hip fracture.
- Tolerance to anxiolytic effects, which may develop after a few weeks of use. (This does not apply to Z-drugs because they are not anxiolytic.)
Adverse effects of both benzodiazepines and Z-drugs

- Dependence: Potent benzodiazepines with short or intermediate half-lives (e.g., alprazolam, lorazepam) appear to carry the highest risk of causing problems with dependence. Psychological or physical dependence can develop over a few weeks or months and is more likely to develop with long-term use or high doses, and in patients with a history of anxiety problems.
- Tolerance to the hypnotic effects, which may develop after only a few days of regular use
- Daytime somnolence
- Dizziness
- Impaired driving performance leading to an increased risk of traffic accidents
- Depression and increased anxiety
- Slowness of mental processes and body movements
- Particularly high risk of overdose when combined with sedative drugs, such as opioids or alcohol
- Increased risk of mortality
- Increased risk of cognitive impairment and delirium
- Increased risk of falls and fractures, especially among older adults

As of September 2020, the FDA requires that all benzodiazepine prescriptions include a boxed warning that addresses the serious risks of abuse, addiction, physical dependence, and withdrawal reactions of benzodiazepine medicines. See https://www.fda.gov/media/142368/download for more information.
Management of Patients on Chronic Benzodiazepines and Z-Drugs

All patients should be encouraged to discontinue chronic use of benzodiazepines and Z-drugs. Providers should create a treatment care plan to help patients with tapering and discontinuation.

- For most people in primary care settings even a minimal intervention, such as a letter with self-help information from the treating physician or a single brief consultation, can be effective in reducing or stopping benzodiazepine use.
- For patients who do not want to stop the drugs, discuss the benefits of stopping. Set the expectation of revisiting the topic at least annually, and more frequently when there are changes in the patient’s care plan.

Risk stratification and intensity of monitoring

<table>
<thead>
<tr>
<th>Table 1. Risk-based monitoring for CHRONIC benzodiazepine or Z-drug use ¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk level</td>
</tr>
</tbody>
</table>
| HIGH | • Age ≥ 65 (HRME)  
• Age < 25 (increased risk of substance use disorder)  
• More than 1 benzo (overdose risk)  
• Benzo + Z-drug (overdose risk)  
• Benzo + opioid (overdose risk)  
• History of substance use disorder  
• Use of alcohol or cannabis  
• Use of gabapentin/pregabalin  
• COPD, severe or uncontrolled respiratory disease, or at risk of respiratory depression  
• History of overdose  
• PTSD  
• Fall risk  
• Problems following benzo care plan | • Evaluation for side effects (e.g. falls)  
• PDMP Summary check at every follow-up  
• Use .BENZOVISIT to document note  
• Use .BENZOCAREPLAN  
• Use .BENZOPROBLIST and/or GHC 30  
• Insomnia Severity Index if for insomnia  
• MH Monitoring Tool and GAD7 if for anxiety | • Office/Video Provider visit every 6 months, including at least one face-to-face office visit per year; others can be virtual  
• UDS required annually |
| STANDARD | None of the above | Same follow-up as above | • Provider visit annually; must be face-to-face office visit  
• UDS optional |

¹ Monitoring visits are required for chronic benzodiazepine or Z-drug use only. The above recommendations do not apply to short-term use of these medications.

² Patients taking opioids with benzodiazepines must have a follow-up visit every 3 months at a minimum. See the KPWA COT Safety Guideline.

For detailed pharmacological information including maximum dosing, monitoring recommendations, and metabolites that may be present in urine drug screen results, see Appendix 1.
Required components of a chronic benzodiazepine or Z-drug visit

1. **Screening, history, and physical exam**

When initiating or monitoring chronic benzodiazepine or Z-drug therapy, perform and document the following:

- Use the SmartPhrase **.BENZOVISIT** to include all the recommended elements of the visit.
- **Medical screening** for issues that affect sedative risk (e.g., COPD, CHF, renal or hepatic compromise, obstructive sleep apnea, pregnancy risk)
- **Patient history and physical exam**
- **Insomnia assessment** using ISI if drugs are being used for insomnia.
- **Depression, anxiety, alcohol and drug use screening** with MH monitoring tool.

*Note:* Annual screening for mental health issues is part of adult standard care.

2. **Prescription monitoring**

Check the patient’s record in the Washington State Prescription Drug Monitoring Program (PDMP) Summary to determine whether the patient is receiving benzodiazepine dosages or dangerous combinations that put them at high risk. The PDMP is a central database that keeps track of schedule II–V medications that patients receive at any pharmacy in the state of Washington. Clinicians are required to check this database every time controlled substances are prescribed for a patient. Data for all controlled substances can be found in the **WA PDMP Summary activity** in HealthConnect.

3. **Urine drug screening**

Urine drug screening (UDS) provides objective data regarding patients on chronic benzodiazepines and can be used to directly improve patient safety. For their safety, it is important that patients take benzodiazepines as prescribed, and this test helps assess whether they are doing so. UDS should also be ordered when seeing patients already on benzodiazepines who are new to the health plan and have no record of recent UDS.

UDS is for medical purposes only. KPWA does not collect samples for use in a court of law or for workplace testing.

Clinicians should have a discussion with the patient before the UDS that includes:

- The purpose of testing
- What will be screened for
- What results the patient expects to see
- Prescriptions or any other drugs the patient has taken
- Actions that may be taken based on the results of the screen
- Possibility of cost to the patient

Patients should be notified that the results will become part of their permanent medical record. For more detailed information on urine drug screening, see **Drug Screen Ordering & Interpretation**.
For patients taking benzodiazepines, use **UDS for pain management**, and choose either the benzos only, opioids only, or opioids and benzos option, for screening and confirmation. This UDS does not include alcohol, fentanyl, methylphenidate, tramadol, or Z-drugs (eszopiclone, zaleplon and zolpidem). If a patient is prescribed any of these excluded drugs, a separate lab test will need to be ordered for each specific drug that the patient is taking.

Order serum drug screen for patients who are taking diuretics or cannot produce urine.

4. **Documentation and coding**

Include GHC.30 (chronic benzodiazepine care plan) on the problem list and use the SmartPhrases **.BENZOPROBLIST** and **.BENZOVISIT**.

5. **Care plan**

The SmartPhrase **.BENZOCAREPLAN** includes all the elements of the treatment plan and **must be used in the After Visit Summary** for the visit to satisfy requirements for the care plan update.
Tapering and Discontinuation

Tapering considerations

Taper planning must be individualized based on the patient's clinical needs, indication for taper, and ability to comply with the care team's tapering instructions, and on the provider's clinical judgment.

- Determine initial step of taper and document rationale in medical record using the SmartPhrase BENZOTAPER (synonym: ZDRUGTAPER).
- **Do not reverse a taper.** A temporary pause in tapering may be indicated to mitigate side effects.
- Assess the patient’s response to the initial dose reduction in the first 1 to 4 weeks.
- Assess the patient’s underlying condition for which the drugs were originally prescribed; discuss alternative treatments as needed.
- Assess the patient for readiness/suitability to taper off benzodiazepines. Patients are considered suitable if they:
  - Are willing and committed, with adequate social support,
  - Have no previous history of complicated drug withdrawal, and
  - Do not have an indication for rapid discontinuation (see Table 3).

If a taper is needed but the patient does not meet the criteria above, or if you have specific questions about tapering, consult Mind Phone or Pharmacy.

- Cognitive behavioral therapy is recommended to help the patient cope with rebound anxiety and to assist with the withdrawal process.
- Consider referral to a specialist for patients who:
  - Have a history of alcohol use disorder or other substance use disorders,
  - Have a concurrent severe medical or psychiatric disorder,
  - Are on a high dose,
  - Are taking stimulants or opioids concurrently, or
  - Have a history of drug withdrawal seizures.
- Reassess taper weekly to monthly based on patient’s response, and prior to each subsequent dose reduction.

Z-drug recommendations

Considering the frequency at which the patient takes the medication, choose one of these options:

- **Stop the Z-drug and start an alternative medication** (such as melatonin, trazodone, doxepin, or mirtazapine).
- **Taper the Z-drug** by decreasing the number of days per week the patient takes the medication (for example: take 6 nights per week x 2 weeks, then 5 nights per week x 2 weeks, and so on).
- **For chronic, long-term Z-drug use** (Bélanger 2009):

<table>
<thead>
<tr>
<th>Z-drug</th>
<th>Taper method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zolpidem</td>
<td>Reduce by ~25% of original dose each week or every other week</td>
</tr>
<tr>
<td></td>
<td>If dose &gt; 10 mg/day IR or 12.5 mg/day CR: slower rate of tapering in conjunction with CBT-I</td>
</tr>
<tr>
<td>Eszopiclone</td>
<td>Reduce by ~25% of original dose (up to 1 mg) each week or every other week</td>
</tr>
<tr>
<td></td>
<td>If dose &gt; 3 mg/day: slower rate of tapering in conjunction with CBT-I</td>
</tr>
<tr>
<td>Zaleplon</td>
<td>Reduce by ~25% of original dose each week or every other week</td>
</tr>
<tr>
<td></td>
<td>If dose &gt; 20 mg/day: slower rate of tapering in conjunction with CBT-I</td>
</tr>
</tbody>
</table>
Benzodiazepine tapering recommendations

The most effective strategy to manage benzodiazepine discontinuation and prevent adverse outcomes associated with severe withdrawal—such as severe seizures—is a gradual taper of benzodiazepines.

- If the patient is established on a long- or intermediate-acting benzodiazepine, taper the medication per Table 3 or see “Switching to a longer-acting benzodiazepine,” p. 12.
- If the patient is established on a short-acting benzodiazepine or one that doesn’t easily allow for small dose reductions, switch to diazepam (patients 64 or younger) or lorazepam (patients 65 and older) and gradually taper per Table 3 or “Switching to a longer-acting benzodiazepine,” p. 12.
- Use the SmartPhrase .AVSBENZOTAPER to educate patients about the tapering process.

| Table 3. Clinical indications and methods for tapering of chronic benzodiazepine therapy |
|---------------------------------|---------------------------------|
| Indication                      | Taper method                    |
| Function is not improved        | SLOW                            |
| Tolerance has developed with long-term prescription | 10% every 2–4 weeks |
| Medication adverse effects indicate risks are greater than benefit | MODERATE |
| Comorbidities increase risk of complication | 10% every week |
| Urine drug screen is consistent with substance abuse concerns, Significant risk of respiratory depression due to unstable clinical condition or recent overdose, or Patient’s behavior suggests possible misuse or diversion of medication. Such behaviors might include: Selling prescription drugs Forging prescriptions Stealing or borrowing drugs Frequently losing prescriptions Aggressive demand for benzodiazepines Injecting oral/topical benzodiazepines Unsanctioned use of benzodiazepines Unsanctioned dose escalation Concurrent use of illicit drugs, including opioids Getting benzodiazepines from multiple prescribers Recurring emergency department visits Concurrent use of alcohol | RAPID |
|                                 | 25% per week and/or Refer patient for chemical dependency or addiction counseling. (See Referral Criteria, p. 14.) |

- A subset of patients will experience clinically significant withdrawal symptoms even with 10% dose reductions and/or gradual tapering. Consider switching these patients to a longer-acting benzodiazepine, see “Switching to a longer-acting benzodiazepine,” p. 12.
- Tapering should be guided by individual choice and severity of withdrawal symptoms. Drug discontinuation may take 3 months to a year or longer. Some people may be able to discontinue the drug in less time.
- Review the patient’s progress frequently to detect and manage problems early and to provide advice and encouragement during and after tapering. Development of withdrawal symptoms can be quite variable and insidious during a taper. A high index of suspicion for withdrawal-related etiology should be held if new symptoms arise during a taper. (See “Treatment of Withdrawal” p. 13 for more information about withdrawal symptoms.)
- If the first attempt is unsuccessful, consider switching to long-acting benzodiazepines in second attempt (see “Switching to a longer-acting benzodiazepine,” p. 12).
- If patient compliance is an issue, consider dispensing medication in 7- or 14-day increments.
Switching to a longer-acting benzodiazepine for tapering

Diazepam (patients aged 64 and under)

There is a lack of good-quality evidence on switching to diazepam, but it can be considered for some people because diazepam has a long half-life (20–80 hours) and thus has fewer fluctuations in plasma levels. It is also available in a variety of strengths and formulations, which facilitates step-wise dose substitutions from other benzodiazepines or Z-drugs and allows for small incremental reductions in dosage. Switching is best carried out gradually, usually in a step-wise fashion.

Switching to diazepam should be considered for individuals who are:

- Using short- to intermediate-acting benzodiazepines (e.g., alprazolam and lorazepam)
- Using preparations that do not easily allow for small reductions in dose (e.g., alprazolam or flurazepam)
- Experiencing difficulty or likely to experience difficulty withdrawing directly from temazepam or Z-drugs due to a high degree of dependency (associated with long duration of treatment, high doses, or history of anxiety problems)

Alprazolam (Xanax) note: Care should be taken not to taper alprazolam too rapidly or to switch to another benzodiazepine too abruptly, as withdrawal seizures are more prone to occur with alprazolam than with other benzodiazepines. If difficulty tapering the last 1–2 mg of alprazolam: taper more gradually (0.25 mg/week) or substitute diazepam gradually over 1 week and taper as usual.

Lorazepam (patients aged 65 and over)

Switching to diazepam in patients aged 65 and over is not recommended, as case reports suggest that it may be associated with delirium. For older adults, lorazepam, oxazepam, and temazepam are the safest options because they don’t have metabolites that can accumulate. Of these, lorazepam is the best in terms of dosing options—available as 0.5, 1, and 2 mg tabs, and as 2 mg/mL oral solution.

How to make the switch

- Substitute diazepam or lorazepam for one dose of the current benzodiazepine at a time, usually starting with the evening or nighttime dose to avoid daytime sedation. Replace the other doses, one by one, at intervals of a few days or a week until the total approximate equivalent dose (Table 4) is reached before starting the reduction.
- For patients on diazepam, the long half-life can enable them to take a single dose at night or a twice-daily dose.
- For patients on lorazepam, twice-daily dosing is recommended.

| Table 4. Approximate dose equivalent to 5 mg diazepam |
|---|---|---|
| Trade name | Half-life (hours) | Dose equivalent to 5 mg diazepam |
| Alprazolam | Xanax | 12–15 | 0.5 mg |
| Chlordiazepoxide | Librium | 5–30 | 10 mg |
| Clonazepam | Klonopin | 18–50 | 0.25–0.5 mg |
| Diazepam † | Valium | 20–80 | 5 mg |
| Lorazepam | Ativan | 10–20 | 1 mg |
| Temazepam | Restoril | 3.5–18.5 | 30 mg |
| Triazolam | Halcion | 1.5–5.5 | 0.25 mg |

† Prescribe 5 mg or 2 mg diazepam tablets only. Starting dose should not exceed 40 mg. Consult with Mental Health and Wellness if considering a higher dose.
Treatment of Withdrawal Symptoms

Acute signs and symptoms of withdrawal

Anxiety-related withdrawal symptoms are common, and include restlessness, agitation, tremors, dizziness, panic attacks, palpitations, shortness of breath, sweating, flushing, shakiness, difficulty swallowing, poor sleep, sensation of choking, and chest pain. There is a wide range of other, less common acute withdrawal symptoms, such as seizures, bowel/bladder problems, changes in appetite, tiredness, faintness, poor concentration, tinnitus and delirium.

Long-term signs and symptoms of withdrawal

Some withdrawal symptoms can persist and may take months or years to resolve, including anxiety, fatigue, depression, poor memory and cognition, motor symptoms (pain, weakness, muscle twitches, jerks, seizures), depersonalization, psychosis, paranoid delusions, rebound insomnia, and abnormal perception of movement.

Prevention and treatment of withdrawal symptoms

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Medication</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure prevention</td>
<td>Carbamazepine</td>
<td>Start 200 mg twice daily, adjust dose weekly up to 400 mg twice daily. Continue for 2–4 weeks after stopping benzodiazepines and then taper anticonvulsant.</td>
</tr>
<tr>
<td></td>
<td>Valproic acid</td>
<td>Start 500 mg twice daily, adjust dose weekly up to 2,000 mg daily. Continue for 2–4 weeks after stopping benzodiazepines and then taper anticonvulsant.</td>
</tr>
<tr>
<td></td>
<td>Propranolol</td>
<td>10 mg three times daily as needed for 3 days</td>
</tr>
<tr>
<td>Tachycardia, hypertension, tremors, sweats, anxiety, restlessness</td>
<td>Clonidine</td>
<td>0.1 mg three times daily as needed for 3 days</td>
</tr>
<tr>
<td>Hypertension, tremors, sweats, anxiety, restlessness</td>
<td>Gabapentin</td>
<td>100–300 mg every 6 hours as needed</td>
</tr>
<tr>
<td></td>
<td>Hydroxyzine</td>
<td>25 mg every 6 hours as needed</td>
</tr>
<tr>
<td></td>
<td>Diphenhydramine</td>
<td>25–50 mg daily before bed as needed</td>
</tr>
<tr>
<td>Insomnia</td>
<td>Gabapentin</td>
<td>100–300 mg daily before bed as needed</td>
</tr>
<tr>
<td></td>
<td>Hydroxyzine</td>
<td>25–50 mg daily before bed as needed</td>
</tr>
<tr>
<td></td>
<td>Diphenhydramine</td>
<td>25–50 mg daily before bed as needed</td>
</tr>
<tr>
<td>Nausea</td>
<td>Promethazine</td>
<td>25 mg every 6 hours as needed</td>
</tr>
<tr>
<td></td>
<td>Metoclopramide</td>
<td>10 mg every 6 hours as needed</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Calcium carbonate</td>
<td>500 mg 1–2 tabs every 8 hours as needed</td>
</tr>
<tr>
<td></td>
<td>Mylanta, Milk of Magnesia</td>
<td>Follow package instructions.</td>
</tr>
<tr>
<td>Pain, fever</td>
<td>Acetaminophen</td>
<td>500 mg every 4 hours as needed, not to exceed 3,000 mg in 24 hours</td>
</tr>
<tr>
<td></td>
<td>Ibuprofen</td>
<td>600 mg every 6 hours as needed</td>
</tr>
</tbody>
</table>

1 In patients with liver impairment, consider topiramate, gabapentin or levetiracetam. Check CBC and liver function tests at baseline.
2 Check CBC and liver function tests at baseline and every 3 months during treatment.
3 These are high-risk medications for the elderly. Please consider alternatives for patients aged 65 and older.
4 Patients with chronic insomnia or worsening anxiety during the taper often do better with cognitive behavioral therapy to address these symptoms during the taper. Refer these patients to Mental Health Access for this specific therapy.
Referral Criteria

Consider consultation with Mental Health and Wellness for patients who have any of the following:

- A history of alcohol use disorder or other drug use disorders
- A concurrent severe psychiatric disorder
- Concurrent use of stimulants or opioids
- A history of drug withdrawal seizures
- Suicidal thoughts
Evidence Summary

The Benzodiazepine and Z-drug Safety Guideline was developed using an evidence-based process, including systematic literature search, critical appraisal, and evidence synthesis.

As part of our improvement process, the Kaiser Permanente Washington guideline team is working towards developing new clinical guidelines and updating the current guidelines every 2–3 years. To achieve this goal, we are adapting evidence-based recommendations from high-quality national and international external guidelines, if available and appropriate. The external guidelines should meet several quality standards to be considered for adaptation. They must: be developed by a multidisciplinary team with no or minimal conflicts of interest; be evidence-based; address a population that is reasonably similar to our population; and be transparent about the frequency of updates and the date the current version was completed.

In addition to identifying the recently published guidelines that meet the above standards, a literature search was conducted to identify studies relevant to the key questions that are not addressed by the external guidelines.

External guidelines meeting KPWA criteria for adaptation/adoption

- 2020 Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults (Conn 2020)
- 2019 Practice Guidelines: Deprescribing Benzodiazepine Receptor Agonists for Insomnia in Adults (Croke 2019)

Key questions addressed in the KPWA evidence review

Comparative effectiveness of benzodiazepines (BZDs) and cognitive behavioral therapy (CBT) used for management of anxiety disorders in adults

- Most guidelines on the treatment of anxiety disorders published by different organizations and countries recommend psychotherapy (including CBT) mainly as a first-line treatment for anxiety disorders. The majority of the guidelines recommend that use of BZD anxiolytics may only be used for a short term (3–6 months). However, both the United Kingdom’s NICE (2014) and the German guidelines (Bandelow 2021) do not recommend the use of BZD anxiolytics in the treatment of anxiety disorders, even for short-term use, except for in critical or exceptional situations.
- There is a lack of recent studies or meta-analyses on the comparative effectiveness of benzodiazepines and cognitive behavioral therapy in adults.
  - A meta-analysis conducted by Bandelow and colleagues (2015) evaluated the pre-post effect sizes for different pharmacological, psychological, and combined treatments used for the three main anxiety disorders (panic disorder with or without agoraphobia, generalized anxiety disorder, and social anxiety disorder). Its results suggest that the average pre-post effects of each of the benzodiazepine, selective serotonin reuptake inhibitor (SSRIs), and serotonin-norepinephrine reuptake inhibitor (SNRIs) classes of medications were higher compared to CBT used alone, but not when CBT was used in combination with drug therapy.
  - An earlier London and Toronto study (Marks 1993) showed that panic attacks ceased with placebo, CBT, or drug therapy (alprazolam), and that relapse was common after alprazolam was stopped, but the gains persisted to 6-month follow-up after the CBT was stopped.
Comparative effectiveness, safety, and tolerability of benzodiazepines or the analogous Z-drugs versus other pharmacological therapies prescribed for managing anxiety disorder in adults (sertraline, venlafaxine, escitalopram, citalopram, fluoxetine, duloxetine, Buspar, mirtazapine)

There is insufficient published evidence from valid head-to-head trials to determine the comparative efficacy, tolerability, and safety of benzodiazepines versus SSRIs or SNRIs used for the treatment of anxiety disorders. The published trials mainly compared the pharmacological therapies (antidepressants in general, serotonergic antidepressants, and benzodiazepines) used for the treatment of anxiety disorders versus placebo.

The trials on benzodiazepines for the treatment of anxiety disorders were smaller studies that compared one BZD compound versus another BZD or versus placebo; were published more than three decades earlier under different requirements (e.g., as indicated in Gomez 2018); and companies sponsoring drug trials were not required to make negative/null findings publicly available. The investigators also indicated that, "most of the BZD trials used compounds with medium-long half-lives (e.g., lorazepam, diazepam), which have different anxiolytic and side-effect profiles than shorter-acting compounds (e.g., alprazolam). The slower-acting BZDs are associated with less risk of dependence relative to alprazolam but may be potentially associated with future development of cognitive decline."

- Du 2021 network meta-analysis that assessed the efficacy and acceptability of different types of antidepressants and benzodiazepines for the treatment of panic disorder in adult patients suggested that escitalopram, venlafaxine, and benzodiazepines had greater efficacy and acceptability than the placebo. Paroxetine, sertraline, fluoxetine, citalopram, and clomipramine were also more efficacious than placebo, but paroxetine and sertraline were statistically significantly less tolerated than benzodiazepines (based on indirect comparisons).
- Gomez 2018 meta-analysis that also indirectly compared the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder showed that the overall effect of SSRIs, SNRIs, and BZDs combined was mild to moderate compared placebo, and that BZDs had a significantly larger effect compared to SSRIs and SNRIs.
- Shinfuku 2019 meta-analysis examined the effectiveness and safety of long-term benzodiazepine use in anxiety disorders. The indirect comparison between BZDs and antidepressants showed no significant difference in effect size between the two classes, and that BZDs had a lower risk of discontinuation.
- Quagliato 2019 meta-analysis that compared the adverse events associated with BZDs versus SSRIs in acute panic disorder treatment suggest that BZDs may be more tolerable than SSRIs in the course of short-term treatment of panic disorder.
- Serious side effects, such as falls, fractures, and cognitive impairment, were not reported.

The results of the published meta-analyses have to be interpreted cautiously due to the limitations of indirect analysis and the methodological quality of the included trials.

Association between benzodiazepines or Z-drugs for treatment of anxiety disorders or other health conditions and the risk of cognitive decline and dementia in older adults

The results of the published studies and meta-analyses on the association between the use of BZDs and related drugs and cognitive decline and dementia are mixed. While some systematic reviews and meta-analyses suggest an association (Baek 2020, Lucchetta 2018, Penninkilampi 2018), others show no association (Hafdi 2020, Nafti 2020).

All published studies are observational prospective or case-control, with variations in: population size and characteristics; data source; setting; degree and definition of cognitive decline; diagnostic criteria for cognitive decline; definition and duration of BZD use; duration of follow-up; adjustment for potential confounders; outcome measures; and other areas.

The majority of the published studies obtained their data from claims and prescription databases; the information on BZD exposure was measured at baseline but not during or at the end of the studies, which
may overestimate the long-term use of the drugs. Moreover, data on medication dosage was not collected in the majority of studies, which does not allow for examining the effect of the exposure by dosage.

In terms of evidence regarding any association of Z-drugs specifically with dementia, the majority of studies combined BZDs with Z-drugs in the analysis, and the few that performed sub-analysis suggested that risk of dementia with Z-drugs was similar to that seen with benzodiazepines.

Due to the design of the published studies, it is difficult to determine whether the association found by some is due to causality or reverse causation (protopathic bias), as insomnia, anxiety, and depression were found to be prodromal symptoms of dementia and can occur several years before a clinical diagnosis of the disease (i.e., there is uncertainty about whether the BZD use was responsible for causing dementia or if it was used to treat its early symptoms).

There is also a potential indication bias, which occurs when the risk of an adverse event is related to the indication for medication use but not the use of the medication itself.

Only RCTs can determine a cause-and-effect association but are not likely to be performed for ethical reasons.

**Association between the prescribing pattern (dose, type, and duration of use) of benzodiazepines or Z-drugs for the treatment of anxiety disorders or other health conditions and increased risk of cognitive decline and dementia in older adults**

There is insufficient published evidence to determine the association between the pattern of using benzodiazepines and Z-drugs (dose, type, and duration of use) and the risk of cognitive decline and dementia in older adults. The published studies consisted of observational cohort studies, nested case control studies, and post hoc analyses of a large RCT, the majority of which were conducted overseas. The results of the studies were inconsistent in regard to the differences between long-acting and short-acting benzodiazepines, and between various exposure loads (duration and dose).

- Penninkilampi systematic review and meta-analysis (2018) suggested that short-acting but not long-acting benzodiazepines were significantly associated with an increased risk of dementia.
- A post hoc analysis of a large prospective study (Hafdi 2020) showed no association between the consistent use of BZD for 2 years and the risk of dementia in the cohort studied.
- A cohort study conducted by Osler (2020) showed that the number of prescriptions and the cumulative dose of benzodiazepines or Z-drugs at baseline were not associated with dementia; however, the analysis of the nested case-control study conducted by the same group of investigators showed slightly higher odds of developing dementia among patients with the lowest rate of benzodiazepine or Z-drug use compared with patients with no lifetime use. Patients with the highest rate of use appeared to have the lowest odds of developing dementia.
- Tapiainen 2018 nested case-control study showed that
  - Any use of BZD and related drugs (Z-drugs) (BZDR) was associated with an increased risk of Alzheimer’s disease (OR 1.19, 95% CI, 1.17 to 1.21) compared with no use.
  - Similar associations were observed with the use of BZD or Z-drug alone, and with short/medium- and long-acting BZDRs.
  - A dose-response relationship between BZDR use and Alzheimer’s disease was observed, but adjustment for other psychotropics removed this relationship, suggesting that the association was at least partially explained by more frequent use of antidepressants. Analysis based on duration of use showed that the risks in all drug categories were the highest in the two groups with longest duration of use (1–5 years and > 5 years) and slightly lowered in groups with shorter use compared to nonusers of each drug. In the fully adjusted model, no risks were observed in the shortest use (1 day to 1 month) and increased until the second longest (1–5 years) duration of use group.

Larger studies with enough statistical power and follow-up duration are needed to determine whether there are differences between long-acting and short-acting benzodiazepines, and between various exposure loads (duration and dose).
Association between benzodiazepines and Z-drugs and increased risk of accidents, falls, and hip fractures in older adults

- The recent published literature on the association between the use of benzodiazepines and Z-drugs and the increased risk of falls, fractures, and injuries consists of meta-analyses of observational studies (Treves 2018, Poly 2020).
- The results of the reviewed meta-analyses suggest that
  - Benzodiazepines and Z-drugs are associated with an increased risk of hip fractures and falls. The risk observed was more pronounced with fractures, as data on falls is more often based on self-report, which may not be always accurate.
  - The risk of hip fracture associated with BZD and Z-drug use is significant among new users, current users, and previous users.
  - Subgroup analysis of Poly 2020 meta-analysis suggests that both the short- or long-acting BZDs are associated with hip fracture.
  - Z-drugs are not safer than BZDs, and short-acting benzodiazepines are not safer than the long-acting drugs.
- Large prospective studies with minimal bias and controlling for confounding factors are needed to provide more accurate evidence on the risk of different benzodiazepines and Z-drugs, as well as their dose, type, and duration of use on the risk of fracture.

Association between benzodiazepine use and risk of death among adults using the drugs for the treatment of insomnia and/or anxiety

Published studies (Xu 2020, Parsaik 2016, Patorno 2017) suggest an association between the use of benzodiazepines and the risk of all-cause mortality. There is insufficient evidence, however, to determine whether the observed association is a causal relationship.

Association between use of benzodiazepines or Z-drugs in adults and risk of suicide

Evaluating the relationship between benzodiazepines and suicide is challenging due to the potential of indication bias. Benzodiazepines are mainly prescribed for patients with sleep disorders or anxiety. Sleep disorders have been identified as a risk factor for suicide ideation, nonfatal suicide attempts, and suicide (Drapeau 2017), and anxiety has been found to increase the risk of suicide ideation and attempts (Bentley 2016).

The literature search did not identify any valid long-term prospective studies that evaluated the causal association of benzodiazepines with the risk of suicide. Only case-control studies or retrospective studies with data from registers were found.

- The published literature suggests that there may be an association between the use of BZD and the risk of suicide, and that the risk of suicide appears to increase with the increasing duration of BZD use.
- Cato and colleagues’ (2019) case-control study examined whether benzodiazepines are associated with an increased risk of suicide, by comparing psychopharmacological interventions between psychiatric patients who committed suicide and matched controls. The analysis showed that BZD prescriptions were more common among cases than controls, with an odds ratio of 1.89 (95% CI, 1.17 to 3.03), and that the association remained significant after adjustment for previous suicide attempts and somatic hospitalizations. No statistically significant differences were seen between the groups in the use of any other subtype of psychopharmaceutical agent. However, this study is limited by the potential for indication bias.
- Boggs (2020) retrospective case control study that evaluated the association between suicide death and concordance with benzodiazepine guidelines showed a significant association between the duration of BZD use and suicide death starting with just 1–2 dispensings. The authors explained that this may be due to higher disease severity associated with benzodiazepine prescribing and/or increased risk for benzodiazepine overdose. The analysis also showed that antidepressants and/or psychotherapy treatments lessened the odds for suicide death among those with 3–8 benzodiazepine dispensings compared to those who used benzodiazepines as monotherapy.
- There is insufficient evidence to determine the association between patterns of BZD and Z-drug dose and type with the risk of suicide.
• There is no evidence to date to determine that the association observed is a cause-and-effect relationship and that it is not due to confounding by indication or other factors.

Incidence of long-term use of benzodiazepines or Z-drugs in adults who start new treatment with these agents, and factors associated with development of long-term use in these new starts

• Low- to moderate-quality evidence from published studies conducted in the US (Gerlach 2018) and overseas (Taipale 2020) suggests that the incidence of long-term use of BZDRs ranged from 20% to around 40% depending on the definition of long-term use (which varied from ≥ 6 to ≥ 12 months), country, population studied, the indication for prescribing a BZDR, index BZD used, and day supply of index prescription.
• The factors associated with long-term use of BZDR in general include older age, receipt of social benefits, psychiatric comorbidities, poor sleep quality, substance abuse, and use of opioids and/or antidepressants, index BZDR used, and the amount supplied in the initial prescription.
• Takano 2019 study showed that compared to BZDs with short half-life, those with medium half-life and not long half-life in the initial prescription were associated with the risk of long-term use.
• Wright and colleagues’ (2021) cohort study that examined the frequency of use and persistent use of benzodiazepines among patients undergoing major and minor surgical procedures showed that one-fifth of benzodiazepine-naive patients prescribed a perioperative benzodiazepine continued its use for the duration of follow-up (90–180 days). Factors associated with persistent use of benzodiazepines were Medicaid recipients, age ≥ 70 years, female gender, presence of medical comorbidities, and/or a diagnosis of anxiety, depression, insomnia, or substance use disorder.

Benefits and harms of deprescribing or tapering benzodiazepines or Z-drugs compared to their continued use in adult patients prescribed these drugs daily for longer than 2 weeks, and for 90 days, for anxiety disorders or insomnia

Based on a systematic review of the literature by the Canadian Clinical Practice Guideline development team (GDT) (Pottie 2018) to investigate the benefits and harms of deprescribing of benzodiazepine receptor agonist (BZRA) use for patients with insomnia, the GDT concluded that the findings suggest that tapering improves cessation rates compared to usual care without an increase in severity of withdrawal symptoms or worsening of sleep.
• Tapering of BZRAs improved cessation rates (low-quality evidence) at 3 months follow-up (RR 3.45, 95% CI, 1.49 to 7.99) when compared to usual care (not receiving any help with benzodiazepine reduction).
• Tapering did not result in increased withdrawal symptoms compared to usual care or continuation, as measured by overall withdrawal symptom scores (such as the benzodiazepine withdrawal symptom questionnaire).
• At 12 months, there was no significant difference in problems sleeping between those who discontinued BZRAs and those who continued using (MD 1.2, 95% CI, -0.48 to 2.88).
• In one study, the tapering group had significantly more problems sleeping at 3 months compared to those continuing BZRAs. However, sleep did not worsen in the tapering group from baseline.

Due to the lack of evidence of substantial harm of deprescribing, and the evidence of potential harm associated with continuing a benzodiazepine receptor agonist (particularly in the elderly), the guideline group rated the recommendation to deprescribe BZRAs in older patients as strong. The recommendation to deprescribe a BZRA in the younger population was rated as weak due to lower risk of adverse effects associated with continuing BZRA use.

Deprescribing strategies/interventions for tapering down and withdrawal in adults who are long-term users of benzodiazepines and/or Z-drugs

• The interventions evaluated in the systematic reviews with meta-analyses and studies (Gould 2014, Tannenbaum 2014, Darker 2015, Reeve 2017, Baandrup 2018, Duo 2018, Evrard 2020, Lynch 2020, Ashworth 2021, Ribeiro 2021, Takeshima 2021) included the following:
  o Brief interventions consisting mainly of written letters signed by prescribers (physician or clinical pharmacist); short consultations by health care professionals recommending
education/discontinuation of the medications; telephone calls; and written educational resources (e.g., information sheets, self-help booklets)

- Psychological interventions: structured CBT performed by trained staff including face-to-face, telephone, computer, and virtual reality interventions; motivational interviewing; letters to patients advising them to reduce or quit BZD use; relaxation studies; counseling delivered electronically; and advice provided by a general practitioner

- Pharmacological interventions to assist in BZD withdrawal, including valproate, pregabalin, captodiame, paroxetine, flumazenil, carbamazepine, pregabalin, paroxetine, alpidem, and magnesium aspartate

- Patient education interventions to raise awareness of harms of chronic BZD use

- Interventions targeting the prescribing physician

- Multicomponent interventions

- All interventions advocated gradual BZD/BZDR dose reduction but had different specific instructions and used different tapering schedules.

- The treatment in the control groups was not always detailed and was reported in many studies and systematic reviews as usual treatment.

- The lack of blinding makes it difficult to determine the placebo effect associated with the intervention.

- Many of the studies and reviews did not specify whether they included Z-drugs when referring to benzodiazepine use. Few would include them (BZRA or BZDR).

The overall results of the published studies and meta-analysis on deprescribing BZDs show the following:

- BZD withdrawal is feasible and safe in the older population. The reported success rates for deprescribing BZDs in older people ranged between studies and systematic reviews from 27% to 80%. The wide variation of the successful deprescribing rates may be attributed to the heterogeneity between the studies in their methodology; participant inclusion/exclusion criteria; definitions of elderly and chronic BZD use; dose, type, and duration of BZD used; population characteristics, including age group, living in the community or nursing homes, comorbidities, others; interventions used; outcomes measures, scales used for clinical outcomes, and whether outcomes were objective, collected from records, physician-reported, or self-reported.

- Moderate-strength evidence shows that psychotherapy (mainly cognitive behavioral therapy [CBT]) is an effective approach for benzodiazepine discontinuation.
  - An earlier meta-analysis of RCTs in older patients (Gould 2014) found that supervised withdrawal with psychotherapy was more effective than other withdrawal interventions in older people (mean ≥ 60 years) for 12 months follow-up.
  - There is evidence on the benefits of standardized counseling and psychotherapy (compared to usual care) in deprescribing BZD. However, the duration of the effectiveness of CBT on discontinuation of BZD varied between studies and meta-analyses:
    - Takeshima (2021) meta-analysis showed that CBT is effective in discontinuing BZD anxiolytics for patients with anxiety disorders up to 12 months of follow-up.
    - An earlier Cochrane systematic review and meta-analysis (Darker 2015) found that CBT plus taper is effective for 3-month time period in reducing BZD use, but is not sustained at or beyond 6 months.

- Moderate-strength evidence shows benefit of patient education in deprescribing BZDs. Direct consumer education of older adults and the discussions with their physician and/or pharmacist on the harms of benzodiazepine use were effective in improving the benzodiazepine discontinuation (NNT=4 in the EMPOWER study [Tannenbaum 2014]).

- A recent meta-analysis (Lynch 2020) showed that the rate of discontinuation of BZRA use was significantly higher at 6 and 12 months among patients who received a brief intervention delivered in primary care compared to those receiving usual care.

- There is insufficient evidence to support the use of motivational interviewing in reducing BZD use.

- The evidence on the benefits and harms of using pharmacological therapy to assist deprescribing of BZDs is very low, contradictory, and insufficient to make any conclusion. While certain drugs such as valproate and tricyclic antidepressants showed some benefit, others were found to be harmful (e.g., Flumazenil may be associated with a high risk of precipitating a severe withdrawal
syndrome; Alpidem may worsen both the probability of discontinuing benzodiazepines and the intensity of withdrawal symptoms [Baandrup 2018]).

• There is insufficient published evidence on the effectiveness of targeting primary care physicians on deprescribing BZDs. The BENZORED cluster RCT (Vicens 2019) is underway and may provide evidence on the effect of an intervention targeting primary care providers to reduce BZD prescription and evaluate the implementation process.

Factors predicting the success or failure of tapering and/or discontinuing the use of benzodiazepines or Z-drugs in adults on long-term use (i.e., enablers and barriers for deprescribing BZD/BZDR)

The overall barriers and enablers reported in the literature (systematic review [Rasmussen 2021], commentary [Ogbonna 2017], and multivariable analysis in the study arm of COME-ON study [Evrard 2020, Anrys 2016]) may be related to patients and/or providers and can be summarized as follows:

1. Patient-related barriers and enablers for deprescribing BZD

   **Barriers**
   - Dependence on BZD to cope with everyday life and/or for a physical or psychological underlying condition
   - Psychological factors and existing personality traits
   - Comorbid dementia or Parkinson’s disease and a history of hospitalization in the past 3 months
   - Fear of a return of the insomnia or anxiety
   - History of alcohol or drug use
   - Lack of family or social support
   - Older age
   - Lack or inadequate awareness of harms and side effects of BZRA treatment, and lack of knowledge of other treatment options
   - Generalized frustration towards the medical profession and disappointment about their treatment, mainly due to limited consultation in decision-making. Some patients described their prescriber as adopting “a one size fits all approach.”
   - Perceived issues with prescribers’ tendency to overprescribe and their lack of sufficient knowledge about BZDs
   - Unsympathetic primary care physicians providing insufficient support
   - Inability to talk openly about their BZDs and feeling stigmatized by their prescribers, who show little effort to understand them. Some interpreted the prescriber attitude as being dismissive or even punitive.

   **Enablers**
   - The patient’s willingness to stop BZRA treatment and return to natural sleep
   - Knowing the harms associated with long-term use and experiencing impairing side effects
   - Recognizing the need to change their beliefs and attitude towards their medication
   - Knowledge about other effective strategies to address underlying issues
   - Voicing their opinion and being actively involving in decision-making
   - Receiving the prescription from their personal primary care provider versus another provider or prescriber
   - Patient's trust of the provider. The most significant influences on trust were the prescriber having a genuine desire to understand the patient, being knowledgeable about BZDs, open communication, shared decision-making, and, to a lesser degree, duration of the relationship.

2. Physician- and/or prescriber-related barriers and enablers for deprescribing BZD

   **Barriers**
   - Lack of knowledge about BZDs and lack of monitoring
   - Expected patient resistance towards deprescribing of BZRA
   - Reluctance to deprescribe treatment from functioning patients
   - Conception that BZRA does not harm
   - Concern about withdrawal symptoms
• General attitude that BZRA should not be avoided, and continued use is necessary
• Unequal balance of power between nurses and physicians

**Enablers**

• Engaging patients in motivational interviewing before beginning the deprescribing process and giving them time to consider the benefits
• The physician’s knowledge of and willingness to follow the guidelines’ instructions that BZRA use is only for the short term
• Physician empathy, demonstrated compassion, and encouragement during tapering
• Satisfactory knowledge about BZDs, diligence in monitoring their use, and providing regular suggestions and encouragement
• Actively involving the patient in shared decision-making
• Flexibility, collaboration with other healthcare providers, and involving nurses in the patients’ medications and evaluation.

**Predictors of continued abstinence after a successful tapering and withdrawal intervention in adults who are long-term users of benzodiazepines or Z-drugs**

There is insufficient published evidence to determine the predictors of long-term success of deprescribing BZD.

Low-strength evidence from one earlier small RCT conducted in the Netherlands (Voshaar 2006) suggests that only one-third of low-dosage benzodiazepine users in the population achieved long-term abstinence with the aid of a supervised gradual withdrawal program.

The analyses of the study suggest five independent predictors associated with a successful long-term continued abstinence. These include:

• Low benzodiazepine dosage before the start of tapering off
• Less severe benzodiazepine dependence
• No use of alcohol
• Active treatment versus no intervention
• Dosage reduction of more than 50% after the minimal intervention

**References**


Guideline Development Process and Team

Development process
The Benzodiazepine and Z-drug Safety Guideline was developed using an evidence-based process, including systematic literature search, critical appraisal, and evidence synthesis. See the Evidence Summary and References section.

This edition of the guideline was approved for publication by the Guideline Oversight Group in January 2022.

Team
The Benzodiazepine and Z-Drug Safety Guideline development process included representatives from the following specialties: Addiction and Recovery Services, Family Medicine, Internal Medicine, Mental Health and Wellness, Pharmacy, Social Work, and Urgent Care.

Clinician lead: Angie Sparks, MD, Medical Director, Clinical Knowledge Development & Support
Guideline coordinator: Avra Cohen, MN, RN, Clinical Improvement & Prevention
Bridget Albright, PA, Urgent Care
Peter Barkett, MD, Internal Medicine
Ryan Caldeiro, MD, Addiction and Recovery Services, Mental Health and Wellness
J. Chau, PharmD, Pharmacy
Megan Gary, MD, Mental Health and Wellness
Dina Greene, PhD, Technical Director of Laboratory
Megan Kavanagh, Patient Engagement Team, Clinical Improvement & Prevention
Kien Nguyen, PharmD, Pharmacy
Kim Painter, MD, Medical Director, Controlled Medications
Rebecca Parrish, MSW, LCISW, Integrated BH Clinical Consultant & Social Work Manager
Kirsten Robinson, MD, Family Medicine
Nadia Salama, MD, PhD, Clinical Epidemiologist, Clinical Improvement & Prevention
Ann Stedronsky, Clinical Publications, Clinical Improvement & Prevention
Melissa Sturgis, PharmD, Pharmacy
Diana Vinh, RN, MPH, Quality Consultant
Appendix 1.
See Drug Screening Ordering & Interpretation for more information on drug screening.

Table A. LONG-acting benzodiazepine comparison
Avoid these medications in adults aged > 64 years. If no alternative treatment is available, use a half-strength dose.

<table>
<thead>
<tr>
<th></th>
<th>Chlordiazepoxide</th>
<th>Clorazepate</th>
<th>Diazepam</th>
<th>Flurazepam</th>
</tr>
</thead>
</table>
| **FDA-approved indications** | Acute alcohol withdrawal  
  Anxiety  
  Preoperative anxiety | Alcohol withdrawal: symptomatic relief of acute withdrawal  
  Anxiety disorders (short-term)  
  Partial seizures (as adjunct therapy) | Acute ethanol withdrawal  
  Anxiety  
  Muscle spasm  
  Preoperative anxiety  
  Seizures  
  Status epilepticus | Insomnia |
| **Off-label indications** | Seizure disorders  
  Rapid eye movement disorders | | | |
| **Anxiety** | **Adults < 65 years**  
  *Mild to moderate anxiety*  
  Usual dose: 5–10 mg, 3–4 times daily  
  *Severe anxiety*  
  Usual dose: 20–25 mg, 3–4 times daily  
  **Debilitated patients**  
  Usual dose: 5 mg, 2–4 times daily  
  **Preoperative anxiety**  
  Oral: 5–10 mg, 3–4 times daily on the days preceding surgery | **Adults < 65 years**  
  *Depressed mood*  
  Usual dose: 15–40 mg/day  
  **Debilitated patients**  
  Initiate at 7.5–15.0 mg/day | **Adults < 65 years**  
  *Depressed mood*  
  Usual dose: 2–10 mg, 2–4 times daily if needed  
  **Debilitated patients**  
  Initiate at 2.0–2.5 mg, 1–2 times daily initially; increase gradually as needed and tolerated | |
| **Insomnia** | | Women < 65 years: 15 mg bedtime  
  Men < 65 years: 15–30 mg bedtime | | |
| **Maximum dose** | Anxiety  
  **Adults < 65 years**: 40–100 mg/day.  
  **Debilitated patients**: 20 mg/day. | Anxiety  
  Generally in 30 mg range, max 60 mg. | Depends on patient.  
  30 mg/day. | |
| **Monitoring** | Long-term therapy  
  CBC, liver enzymes, renal function; signs and symptoms of suicidality (e.g., anxiety, depression, behavior changes) | | Daytime alertness  
  Respiratory rate  
  Behavior profile | |
| **Routinely detected in UDS** | Yes | Yes | Yes | Yes |
| **Expected confirmation result in UDS** | Nordiazepam and/or oxazepam | Nordiazepam and/or oxazepam | Nordiazepam, oxazepam, and/or temazepam | Hydroxyethylflurazepam |
| **Half-life (hrs)** | Parent: 24–48  
  Active metabolite: 14–95 | 20–160 | Parent: 44–48  
  Active metabolite: 100 | Parent: 2–3  
  Active metabolite: 74–113 |
### Appendix 1.
See Drug Screening Ordering & Interpretation for more information on drug screening.

<table>
<thead>
<tr>
<th>Table B. INTERMEDIATE-acting benzodiazepine comparison</th>
<th>Avoid these medications in adults aged &gt; 64 years. If no alternative treatment is available, use a half-strength dose.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA-approved indications</strong></td>
<td><strong>Alprazolam</strong></td>
</tr>
<tr>
<td>Anxiety disorders</td>
<td>Panic disorder</td>
</tr>
<tr>
<td>Panic disorder</td>
<td>Seizure disorders</td>
</tr>
<tr>
<td><strong>Off-label indications</strong></td>
<td><strong>Alprazolam</strong></td>
</tr>
<tr>
<td>Perioperative anxiety</td>
<td>Bipolar disorder (manic or mixed episodes)</td>
</tr>
<tr>
<td>Burning mouth syndrome</td>
<td>Essential tremor</td>
</tr>
<tr>
<td>REM sleep behavior disorder</td>
<td>Restless legs syndrome</td>
</tr>
<tr>
<td>Tardive dyskinesia</td>
<td>Tic disorders</td>
</tr>
<tr>
<td><strong>Anxiety</strong></td>
<td><strong>Adult IR</strong></td>
</tr>
<tr>
<td>0.25–0.5 mg, 3 times daily</td>
<td>0.25 mg, 2 times daily, titrated every 3 days as needed to target of 1 mg/day, max of 4 mg/day</td>
</tr>
<tr>
<td><strong>Insomnia</strong></td>
<td></td>
</tr>
<tr>
<td>REM sleep behavior disorder</td>
<td>0.25–2.0 mg, 30 min prior to bedtime. Max 4 mg</td>
</tr>
<tr>
<td></td>
<td><strong>Adults &lt; 65 years</strong></td>
</tr>
<tr>
<td></td>
<td>0.5–2.0 mg at bedtime (Winkelman 2015)</td>
</tr>
<tr>
<td><strong>Maximum dose</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 mg/day</td>
</tr>
<tr>
<td><strong>Comments</strong></td>
<td><strong>Manufacturer notes on dosing for panic disorder</strong></td>
</tr>
<tr>
<td></td>
<td>IR: 0.5 mg, 3 times daily. Mean effective dose 5–6 mg/day in 3 or 4 divided doses. Some patients may require as much as 10 mg/day</td>
</tr>
<tr>
<td></td>
<td>ER: 0.5–1.0 mg once daily, may be titrated to range of 3–6 mg/day</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Relationship between serum concentration and seizure control is not well established. Therapeutic doses have been associated with serum concentrations of ~15–70 ng/mL (Pataslos 2008)</td>
</tr>
<tr>
<td></td>
<td>CBC, liver function tests, LDH (if high dose, continuous IV use, or IV use in renal impairment, review of Scr, BUN, Serum lactate, osmolal gap, clinical signs of propylene glycol toxicity also recommended.)</td>
</tr>
<tr>
<td><strong>Routinely detected in UDS</strong></td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Expected confirmation result in UDS</strong></td>
<td>Alphahydroxyalprazolam</td>
</tr>
<tr>
<td><strong>Half-life (hrs)</strong></td>
<td>6–27</td>
</tr>
</tbody>
</table>

### References

Appendix 1.
See Drug Screening Ordering & Interpretation for more information on drug screening.

Table C. SHORT-acting Benzodiazepine and Z-drug comparison
Avoid these medications in adults aged > 64 years. If no alternative treatment is available, use a half-strength dose.

<table>
<thead>
<tr>
<th></th>
<th>Triazolam</th>
<th>Eszopiclone</th>
<th>Zaleplon</th>
<th>Zolpidem</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA-approved indications</strong></td>
<td>Short-term treatment of insomnia (generally 7–10 days)</td>
<td>Insomnia</td>
<td>Short-term treatment of insomnia</td>
<td>IR, SL, and oral spray forms</td>
</tr>
<tr>
<td><strong>Off-label indications</strong></td>
<td>Oral sedation prior to outpatient dental procedures</td>
<td>Use lowest effective dose. Adults 0.25 mg at bedtime. 0.125 mg may be sufficient in some patients</td>
<td>Adult 10 mg immediately before bedtime (range: 5–20 mg). 5 mg may be sufficient (max 20 mg)</td>
<td>Women IR: 5 mg immediately before bedtime</td>
</tr>
<tr>
<td><strong>Insomnia</strong></td>
<td>Adults 0.25 mg at bedtime. 0.125 mg may be sufficient in some patients</td>
<td>Debilitated patients 1 mg immediately before bedtime (max 2 mg)</td>
<td>Debilitated 5 mg immediately before bedtime (max 10 mg)</td>
<td>Men ER: 6.25 mg immediately before bedtime</td>
</tr>
<tr>
<td><strong>Maximum dose</strong></td>
<td>Adults: 0.5 mg/day</td>
<td>Adults: 3 mg, Debilitated or geriatric: 2 mg</td>
<td>Adults: 20 mg, Debilitated or geriatric: 10 mg</td>
<td>IR: 10 mg.</td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Daytime alertness</td>
<td>Respiratory rate</td>
<td>Respiratory rate (in patients with compromised respiration)</td>
<td>ER: 12.5 mg immediately before bedtime</td>
</tr>
<tr>
<td><strong>Routinely detected in UDS</strong></td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Expected confirmation result in UDS</strong></td>
<td>Not detected in common benzodiazepine confirmation; must order as miscellaneous test</td>
<td>Not detected in common benzodiazepine confirmation; must order specific test in EPIC</td>
<td>Not detected in common benzodiazepine confirmation; must order specific test in EPIC</td>
<td>Not detected in common benzodiazepine confirmation; must order specific test in EPIC</td>
</tr>
<tr>
<td><strong>Half-life (hrs)</strong></td>
<td>1.5–5.5</td>
<td>~ 6</td>
<td>~ 1</td>
<td>1.4–4.5</td>
</tr>
</tbody>
</table>